Brief: Bluejay Diagnostics Successfully Enrolls 545 Patients In Symon™ Ii Study And Advances Manufacturing Readiness Into 2026
17/02/2026 11:38
Feb 17 (Reuters) - Bluejay Diagnostics Inc BJDX.O: BLUEJAY DIAGNOSTICS SUCCESSFULLY ENROLLS 545 PATIENTS IN SYMON™ II STUDY AND ADVANCES MANUFACTURING READINESS INTO 2026 Source text: ID:nGNX4Fv7Md Further company coverage: BJDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bluejay Diagnostics
See all newsBrief: Bluejay Diagnostics Announces Successful Completion Of Enrollment In The Symon-II Multicenter Clinical Validation Study
Brief: Bluejay Diagnostics And Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics Q1 net loss unchanged
Brief: Bluejay Diagnostics, Inc. Announces Completion Of 624 Patient Enrollments In Symon-Ii Pivotal Clinical Trial
Brief: Bluejay Diagnostics Provides Corporate Update And 2026 Strategic Outlook